

19 February 2026

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Alcidion Secures Dual AU and UK Medical Device Registration for AI Capability, Unlocking Commercial Deployment Across Core Markets

Melbourne, Victoria | [Alcidion Group Limited](#) (ASX:ALC) (**'Alcidion'** or the **'Company'**) advises that its Miya Precision Concept Detection capability has been registered as a Class I Software as a Medical Device (SaMD) on the Australian Register of Therapeutic Goods (ARTG #522634) and with the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA).

This dual registration enables Alcidion to commercially deploy the AI-assisted capability as a regulated clinical tool across Australia and the United Kingdom, the Company's two largest markets, strengthening product positioning and expanding new sales opportunities to participate in procurement processes that require certified medical software.

This milestone advances Alcidion's AI commercialisation strategy and strengthens its competitive position in regulated healthcare technology markets. With healthcare providers in both regions increasingly mandating SaMD certification for AI enabled tools, Alcidion is now positioned to offer Concept Detection to its existing installed base as well as to new customers seeking compliant, clinician-supportive AI Capabilities.

Concept Detection is an AI-assisted feature within the Miya Noting module of Alcidion's Miya Precision platform. It analyses clinicians' free-text notes to identify medical concepts and suggest associated SNOMED CT codes (coding system for standardising medical terminology), supporting structured clinical documentation, workflow efficiency and improved data quality. All suggested concepts require clinician review and validation before inclusion in the patient record ensuring that the software functions strictly as a clinical decision-support tool.

Alcidion currently supports healthcare organisations across Australia and the United Kingdom through its installed base of Miya Precision deployments. The Concept Detection capability will be offered as an optional module within the platform, creating an opportunity to expand functionality and value delivered to existing customers while supporting new sales. This expanded functionality of Miya Precision further validates the Company's ability to innovate and commercialise technology that helps solve daily challenges of healthcare organisations.

Underpinning the Concept Detection and future AI-enabled capabilities, Alcidion has developed a proprietary Miya AI Service that provides a secure and controlled architecture for deploying AI functionality within healthcare environments. The Miya AI Service is specifically designed to support Miya Precision customers to take advantage of the latest developments in AI for Healthcare.

Alcidion Managing Director and CEO Kate Quirke said:

"Achieving regulatory registration in both Australia and the United Kingdom is an important milestone that clears the path for commercial deployment of our AI assisted clinical documentation capabilities across our two largest markets. Healthcare organisations increasingly require certified medical software before adoption, and this registration allows us to deliver this capability across our existing customer base and to new customers in regulated environments.

With this foundation in place, we can now extend these capabilities across our existing Miya Precision customers and to new health systems seeking dependable, AI enabled workflows.”

— ENDS —

Authorised for ASX release by the Board of Directors of Alcidion Group Limited

For further information, please contact:

Investor Relations

investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion’s mission to improve patient outcomes.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

© Alcidion Group Limited 2025